← Oncology Approval Tracker

FDA DECISION ·

Imdelltra

tarlatamab-dlle · Amgen

Accelerated approvalNew therapySmall cell lung cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

LATER FDA ACTION

Traditional approval granted on Nov 19, 2025

FDA Project Confirm ↗

APPROVED USE

What FDA approved

Adults with extensive-stage small cell lung cancer that progressed on or after platinum-based chemotherapy.

LAMPGEN ANALYSIS

Why it matters

The DLL3-directed T-cell engager introduced a different treatment approach after platinum chemotherapy. The 2024 action was accelerated. The FDA granted traditional approval in November 2025.

What research teams should watch

Design step-up visits around the observation requirements, with clear plans for cytokine release syndrome and neurologic changes.

PRIMARY RECORDS

Sources